Our latest special report looks at the investment in early translational cancer research for the 2005 to 2010 period, updating an earlier analysis for 2005 to 2007. This report reveals that the investment in early translational cancer research outpaced that for cancer research overall and grew for all funding sectors from 2005–2006 to 2009‒2010. Provincial government organizations, primarily in Ontario, and to a lesser extent, Alberta were the key drivers of this increased investment. Of the four modalities—drugs, biomarkers, interventive devices, and lifestyle alterations—investment in early translational drug research was highest at 54% of the total early translational research investment, followed by biomarker research at 35%. To access this report and companion slide deck, click here.